GlassScriptPhysician profile
Stacy Ann Wright
NPI 1568098333
$2,105.60
in general payments reported to CMS, 2019-2025
23 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $600 · 2023: $519 · 2024: $413 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.13 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $221.98 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $217.59 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $214.77 | 2023-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $177.75 | 2022-2025 | Belsomra, Steglatro, Verquvo |
| Novo Nordisk INC | $169.86 | 2022-2025 | Rybelsus, Ozempic |
| Amgen INC. | $166.88 | 2022-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $141.78 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.97 | 2025 | Jardiance |
| Smith+Nephew, INC. | $104.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.75 | 2022-2025 | |
| Pfizer INC. | $95.00 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $81.72 | 2023-2025 | Farxiga, Breztri |
| Dexcom, INC. | $60.07 | 2024-2025 | Dexcom G6 Transmitter |
| Alnylam Pharmaceuticals INC. | $40.56 | 2022 | |
| Idorsia Pharmaceuticals US INC | $35.29 | 2022-2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $29.55 | 2022 | |
| Opko Pharmaceuticals, LLC | $22.24 | 2022 | |
| Optinose US, INC. | $19.92 | 2024 | |
| Exact Sciences Corporation | $18.94 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $18.64 | 2022 | |
| Shield Therapeutics INC | $15.71 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.